Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 15 3 2025 09 25 Platelet-Rich Plasma in Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis 521 532 10.34172/apb.025.45444 EN Sakineh Hajebrahimi https://orcid.org/0000-0003-1494-7097 Fateme Tahmasbi https://orcid.org/0000-0002-0652-7693 Elham Jahantabi https://orcid.org/0000-0002-8209-2150 Gholamreza Hosseinpour Rajesh Taneja Hanieh Salehi-Pourmehr https://orcid.org/0000-0001-9030-2106 Journal Article 10.34172/apb.025.45444 2025 03 23 2025 08 27 Purpose: This systematic review aims to critically evaluate the safety and efficacy of PRP therapy in managing interstitial cystitis/bladder pain syndrome (IC/BPS). Methods: Two researchers independently searched related Databases and collected all studies from inception to December 5, 2023. Outcome indicators of symptom relief were pain scores self-assessment using the VAS system, IC symptoms using the O’Leary-Sant score (OSS), urinary frequency, nocturia, post-void residual (PVR), voided volume, and functional bladder capacity. Results: Among 372 retrieved articles, 13 studies, including 426 patients, were included. The pain of patients decreased significantly after treatment with platelet-rich plasma (PRP) compared to the baseline values (MD: -1.93, 95% CI: -2.28, -1.58). All subgroup analyses revealed a decrease in VAS scores after PRP injection. IC symptoms using OSS, and ICSI decreased significantly after treatment. Conclusion: PRP therapy as a new and successful course of treatment may be a novel therapeutic approach in IC/BPS cases. More study with the control arm is required to enhance treatment regimens for this difficult condition and to better understand the mechanisms of action of PRP in IC/BPS.